A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alvina Chu, MD
Pharmacyclics LLC.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
55 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Adelaide, Australia
- Facility name not stated
Coburg, Australia
- Facility name not stated
East Melbourne, Australia
- Facility name not stated
Fremantle, Australia
- Facility name not stated
Antwerp, Belgium
- Facility name not stated
Bruges, Belgium
- Facility name not stated
Brussels, Belgium
- Facility name not stated
Ghent, Belgium
- Facility name not stated
Kortrijk, Belgium
- Facility name not stated
Leuven, Belgium
- Facility name not stated
Roeselare, Belgium
- Facility name not stated
Edmonton, Alberta, Canada
- Facility name not stated
Cologne, Germany
- Facility name not stated
Dresden, Germany
- Facility name not stated
Heidelberg, Germany
- Facility name not stated
Munich, Germany
- Facility name not stated
Ulm, Germany
- Facility name not stated
Auckland, New Zealand
- Facility name not stated
Christchurch, New Zealand
- Facility name not stated
Gothenburg, Sweden
- Facility name not stated
Lund, Sweden
- Facility name not stated
Stockholm, Sweden
- Facility name not stated
Ankara, Turkey (Türkiye)
- Facility name not stated
Gaziantep, Turkey (Türkiye)
- Facility name not stated
Istanbul, Turkey (Türkiye)
- Facility name not stated
Izmir, Turkey (Türkiye)
- Facility name not stated
Kayseri, Turkey (Türkiye)
- Facility name not stated
Bournemouth, United Kingdom
- Facility name not stated
Glasgow, United Kingdom
- Facility name not stated
Leeds, United Kingdom
- Facility name not stated
Leicester, United Kingdom
- Facility name not stated
Liverpool, United Kingdom
- Facility name not stated
London, United Kingdom
- Facility name not stated
Manchester, United Kingdom
- Facility name not stated
Newcastle upon Tyne, United Kingdom
- Facility name not stated
Oxford, United Kingdom
- Facility name not stated
Plymouth, United Kingdom
- Facility name not stated
Phoenix, Arizona, United States
- Facility name not stated
Duarte, California, United States
- Facility name not stated
Greenbrae, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2013
- Primary completion
- 30 Jun 2014
- Completion
- 30 Apr 2016
- Last update posted
- 27 Feb 2017
- Registered enrollment
- 145
- Registry id
- NCT01744691
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.